SG-BCC 2021 - 17th St.Gallen International Breast Cancer Conference (Virtual Meeting)
Mar 17 - Mar 21, 2021 | ViennaAustria
LARVOL is not affiliated with 17th St.Gallen International Breast Cancer Conference (Virtual Meeting) and all trademarks, logos, and brand names are property of their respective owners
Showing 24 abstracts linked to Trials
[VIRTUAL] Patients’ quality of life and side effect perceptions in monarchE, a study of abemaciclib plus endocrine therapy in adjuvant treatment of HR+, HER2-, node-positive, high- risk, early breast cancer
[VIRTUAL] 5-year follow-up of the safety, tolerability and efficacy of subcutaneous trastuzumab for the adjuvant treatment of HER2-positive early breast cancer. Results from the SafeHER Phase III trial
[VIRTUAL] Safety outcomes from monarchE: Phase 3 study of abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER-2-, node-positive, high risk, early breast cancer
[VIRTUAL] Bringing diarrhea under CONTROL: dose escalation reduces neratinib-associated diarrhea and improves tolerability in HER2-positive early-stage breast cancer
[VIRTUAL] Continued efficacy of neratinib in patients with HER2-positive (HER2+) early-stage breast cancer: final overall survival (OS) analysis from the randomized phase 3 ExteNET trial
[VIRTUAL] Neoadjuvant niraparib in patients with HER2-negative, BRCA-mutated resectable breast cancer
[VIRTUAL] Neoadjuvant and adjuvant treatment of patients with HER2- positive early breast cancer
[VIRTUAL] Genomic tests for selecting therapy in adjuvant treatment of ER+ breast cancer (BC)
[VIRTUAL] Integrating CDK 4-6 in the treatment of patients with early breast cancer
[VIRTUAL] Axillary surgery in node-positive breast cancer
[VIRTUAL] Adjuvant decision making in the era of limited nodal information
[VIRTUAL] PARP inhibitors in treatment of early stage breast cancer
[VIRTUAL] Neratinib as extended adjuvant therapy in patients with HER2-positive/HR-positive early breast cancer: German HTA-driven analyses from the ExteNET study
[VIRTUAL] Extended adjuvant treatment of patients with HER2+ early breast cancer with neratinib: a multi-centric, prospective, non-interventional study (NIS) in Germany and Austria (ELEANOR)
[VIRTUAL] (Trial in progress) A real-life prospective, observational, post-authorisation safety study in adult breast cancer patients treated with neratinib in extended adjuvant in Europe: the NERLYFE study